Can Diet and the Gut Microbiome Improve Immunotherapy Response?

Can Diet and the Gut Microbiome Improve Immunotherapy Response?

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for many cancers, producing durable responses in diseases that were once associated with poor outcomes. Yet only a subset of patients achieves long-term benefit, highlighting the need to better understand the host-related factors that influence immunotherapy efficacy

Among these factors, the gut microbiome has emerged as one of the most important regulators of antitumor immunity. At the same time, epidemiological studies have consistently reported an intriguing paradox: patients with higher body mass index (BMI) often experience better responses to immune checkpoint inhibitors. Whether this observation reflects obesity itself or other biological factors has remained unclear

A landmark study published in Nature, “Diet–microbiome synergy underlies obesity-associated immunotherapy efficacy” by Lysanne Desharnais, Anikka Swaby, Meriem Messaoudene, Samuel Doré, Miranda W. Yu, Benoit Fiset, Valérie Breton, Mayra Ponce, Yongjia Hu, Liam Wilson, Mark Sorin, Ye Wang, Ken Dewar, Michael Pollak, Arielle Elkrief, Bertrand Routy, Logan A. Walsh, and Daniela F. Quail, provides new mechanistic insight into this relationship. Rather than identifying obesity itself as the determinant of immunotherapy response, the investigators demonstrate that the interaction between diet and the gut microbiome plays a central role in shaping antitumor immunity.

Gut Microbiome as a Predictor of Dual Checkpoint Inhibition Benefit in Non–Small Cell Lung Cancer

What Is the Gut Microbiome?

The gut microbiome is the collection of trillions of microorganisms—including bacteria, fungi, viruses, and archaea—that inhabit the gastrointestinal tract. Although once considered primarily important for digestion, the gut microbiome is now recognized as a major regulator of systemic immunity

Microbial metabolites constantly interact with immune cells, influencing dendritic cell maturation, macrophage polarization, T-cell activation, cytokine production, and immune tolerance. Because immune checkpoint inhibitors rely on an active immune system, alterations in gut microbial composition can significantly influence treatment efficacy

Several clinical studies have previously shown that patients with favorable gut microbiota are more likely to respond to PD-1 or PD-L1 blockade, while antibiotic-induced disruption of the microbiome has been associated with poorer clinical outcomes

Why Is Obesity Linked to Better Immunotherapy Outcomes?

For years, oncologists have observed what has become known as the “obesity paradox.” Surprisingly, several retrospective clinical studies have reported improved responses to immune checkpoint inhibitors among overweight and obese patients, particularly in melanoma and lung cancer

However, obesity is also associated with chronic inflammation, insulin resistance, metabolic dysfunction, and increased cancer risk. These seemingly contradictory observations suggested that body weight alone could not explain improved immunotherapy responses

The study by Desharnais and colleagues sought to answer a fundamental question:

Is it obesity itself that improves immunotherapy response, or is another biological factor responsible?

Study Design

To address this question, the investigators developed one of the most comprehensive dietary immunotherapy models reported to date

Instead of comparing only lean versus obese animals, they designed 12 distinct dietary models representing a broad spectrum of human eating patterns, including:

• High-fat diet
• Western diet
• Mediterranean diet
• Japanese diet
• Vegan diet
• Ketogenic diet
• Low-fat diet
• Fiber-enriched diets containing psyllium, pectin, or inulin

These diets differed not only in fat content but also in proteinrofiles, allowing the investigators to separate the effects of body weight from those of diet composition. Mice were maintained on these diets before receiving anti-PD-1 immunotherapy, while metabolic status, immune cell populations, gut microbiota, and treatment responses were comprehensively analyzed

Diet Matters More Than Obesity

One of the study’s most important findings was that body weight and metabolic dysfunction were poor predictors of immunotherapy response

Although several obesity-inducing diets enhanced anti-PD-1 efficacy, others did not. Conversely, some lean dietary models also demonstrated favorable responses

These findings indicate that dietary composition—not obesity itself—is the dominant factor influencing immune checkpoint inhibitor sensitivity. The investigators concluded that the biological interaction between diet and the gut microbiome better explains the “obesity paradox” than BMI alone

The Gut Microbiome Shapes Immunotherapy Response

Sequencing of fecal bacterial communities revealed striking differences among dietary groups

Rather than simply changing body weight, different diets generated distinct microbial ecosystems. Mice that responded well to anti-PD-1 therapy consistently exhibited microbiomes enriched with bacterial populations associated with immune activation, whereas resistant diets produced very different microbial signatures

Importantly, microbial diversity alone did not explain treatment outcomes. Instead, the presence or absence of specific bacterial communities appeared to determine whether tumors remained sensitive or resistant to checkpoint blockade

Lactobacillus johnsonii Emerged as a Key Beneficial Species

Among all bacterial species analyzed, Lactobacillus johnsonii consistently emerged as one of the strongest microbial correlates of successful immunotherapy. Metagenomic analyses identified this organism as being highly enriched in dietary conditions associated with effective anti-PD-1 responses

To determine whether this association was causal, investigators colonized germ-free mice with Lactobacillus johnsonii. However, bacterial colonization alone was not sufficient. The greatest therapeutic benefit occurred only when Lactobacillus johnsonii was combined with a favorable dietary environment, demonstrating that diet and microbiota function synergistically rather than independently

This finding suggests that successful immunotherapy depends not only on which bacteria are present but also on whether the surrounding nutritional environment supports their metabolic activity

Diet-Switch Experiments

To determine whether dietary changes could rapidly influence immunotherapy, the investigators performed diet-switch experiments. Remarkably, mice initially resistant to anti-PD-1 therapy became responsive after switching to a favorable diet shortly before treatment. Conversely, changing responsive mice to an unfavorable diet reduced treatment efficacy

These experiments demonstrated that immune responsiveness can change rapidly following dietary modification, even before substantial alterations in body weight occur. The associated microbiome also changed within days, suggesting that short-term dietary interventions may rapidly remodel immune function through microbial mechanisms

Fecal Microbiota Transplantation

The investigators next examined whether favorable gut microbiota could restore immunotherapy sensitivity

Using fecal microbiota transplantation (FMT), they demonstrated that dietary context remained critically important. Even after receiving microbiota from non-responder donors, mice maintained on a favorable diet regained sensitivity to anti-PD-1 therapy.Similarly, mice receiving fecal microbiota from patients with high BMI demonstrated greater responsiveness to checkpoint inhibition than those receiving microbiota from lean donors

These findings suggest that diet helps determine whether transplanted microbial communities successfully establish an immune-supportive ecosystem, highlighting an important interaction between nutrition and microbiome-based therapies

Microbial Metabolites Link Diet to Antitumor Immunity

Beyond bacterial composition, the investigators explored how microbial metabolism influences immune function. Metabolomic analyses identified enrichment of aromatic amino acid metabolic pathways, particularly those involving tryptophan and tyrosine

One metabolite received particular attention: desaminotyrosine (DAT). DAT was produced through interactions between favorable dietary conditions and Lactobacillus johnsonii, and enhanced the functional activity of cytotoxic T cells by increasing production of key effector cytokines, including interferon-γ and tumor necrosis factor-α

Supplementing mice with DAT restored responsiveness to anti-PD-1 therapy in otherwise resistant dietary models, providing strong evidence that microbial metabolites themselves can directly regulate immunotherapy efficacy

Clinical Implications

Although this work was conducted primarily in preclinical models, its translational implications are substantial

The findings suggest that optimizing immunotherapy may eventually extend beyond drug selection alone to include deliberate modulation of the patient’s gut ecosystem

Potential future strategies include:

• Personalized nutritional interventions before immunotherapy
• Targeted manipulation of the gut microbiome
• Fecal microbiota transplantation
• Administration of beneficial bacterial strains
• Development of microbial metabolite–based therapeutics
• Combined dietary and microbiome optimization to improve checkpoint inhibitor efficacy

The authors emphasize that they do not advocate long-term obesogenic diets because of their well-established health risks. Instead, the study highlights the possibility that short-term dietary modulation or microbiome-directed interventions may become practical strategies for enhancing antitumor immunity

Looking Ahead

The study by Desharnais and colleagues shifts the conversation beyond BMI and obesity toward a more nuanced understanding of host biology. Their work suggests that diet, the gut microbiome, and microbial metabolism function together as an integrated immunological system capable of influencing responses to immune checkpoint inhibitors

Rather than viewing nutrition as supportive care alone, these findings position dietary modulation as a potential component of future precision immuno-oncology. While additional clinical studies are needed before these strategies can be incorporated into routine practice, this work provides compelling evidence that manipulating the diet–microbiome axis may represent one of the next frontiers in improving cancer immunotherapy outcomes

You Can Read Full Article Here

• Immune Oncology

cancercancer immunotherapydietgut microbiomeImmune Checkpoint InhibitorsOncoDailyOncoDaily IOOncology